| Stock Name | 荃信生物－Ｂ |
|---|---|
| Stock Code | 02509 |
| Company Full Name | 荃信生物－Ｂ |
| Industry | 醫療保健 |
| Principal Activities | 公司是中國一家完全專注于針對自身免疫及過敏性疾病生物療法的臨床階段生物科技公司，擁有自主研發的藥物管線及完善的商業級規模內部生產能力。 |
| Listing Date | 2024-03-20 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國江蘇省泰州市藥城大道907號1號樓1310室 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.qyuns.net/ |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No data |
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 19.80 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 82.0% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 42,387,840 |
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 200 | HK$ 0 |
| 2 lots | 400 | HK$ 0 |
| 3 lots | 600 | HK$ 0 |
| 4 lots | 800 | HK$ 0 |
| 5 lots | 1,000 | HK$ 0 |
| 6 lots | 1,200 | HK$ 0 |
| 7 lots | 1,400 | HK$ 0 |
| 8 lots | 1,600 | HK$ 0 |
| 9 lots | 1,800 | HK$ 0 |
| 10 lots | 2,000 | HK$ 0 |
| 15 lots | 3,000 | HK$ 0 |
| 20 lots | 4,000 | HK$ 0 |
| 25 lots | 5,000 | HK$ 0 |
| 30 lots | 6,000 | HK$ 0 |
| 35 lots | 7,000 | HK$ 0 |
| 40 lots | 8,000 | HK$ 0 |
| 45 lots | 9,000 | HK$ 0 |
| 50 lots | 10,000 | HK$ 0 |
| 60 lots | 12,000 | HK$ 0 |
| 70 lots | 14,000 | HK$ 0 |
| 80 lots | 16,000 | HK$ 0 |
| 90 lots | 18,000 | HK$ 0 |
| 100 lots | 20,000 | HK$ 0 |
| 150 lots | 30,000 | HK$ 0 |
| 200 lots | 40,000 | HK$ 0 |
| 250 lots | 50,000 | HK$ 0 |
| 300 lots | 60,000 | HK$ 0 |
| 350 lots | 70,000 | HK$ 0 |
| 400 lots | 80,000 | HK$ 0 |
| 450 lots | 90,000 | HK$ 0 |
| 500 lots | 100,000 | HK$ 0 |
| 600 lots | 120,000 | HK$ 0 |
| 700 lots | 140,000 | HK$ 0 |
| 800 lots | 160,000 | HK$ 0 |
| 900 lots | 180,000 | HK$ 0 |
| 1,000 lots | 200,000 | HK$ 0 |
| 1,500 lots | 300,000 | HK$ 0 |
| 2,000 lots | 400,000 | HK$ 0 |
| 2,500 lots | 500,000 | HK$ 0 |
| 3,012 lots | 602,400 | HK$ 0 |
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
| First Day Close | HK$ 24.5 |
|---|---|
| First Day Open | HK$ 27.4 |
| First Day Change | 23.74% |
| First Day Volume | 2308200.0 |
| First Day Turnover | 61672700.0 |
| Use of Proceeds | 1、約30.1%或49.2百萬港元將分配至核心產品QX002N的開發及注冊； 2、約54.6%或89.3百萬港元將分配至其他核心產品QX005N的開發及注冊； 3、約8.7%或14.2百萬港元將分配至QX004N的開發及注冊； 4、約1.9%或3.1百萬港元將分配至QX006N的臨床試驗、QX006N準備注冊文件以及CMC成本； 5、約4.7%或7.7百萬港元將分配至若干其他資產的研發和藥物發現。 |
|---|
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 蜂投资本有限公司 | 39,140,640 HKD | — | 16.41% | — | 6 months | 2024-09-20 |
| 2 | 华东医药投资控股(香港)有限公司 | 39,140,640 HKD | — | 16.41% | — | 6 months | 2024-09-20 |
| 3 | 健鑫医药科技有限公司 | 117,421,920 HKD | — | 49.23% | — | 6 months | 2024-09-20 |
| Chairman | 裘霽宛 |
|---|---|
| Company Secretary | 胡衍保 |
| Major Shareholders & Holdings | 杭州荃毅投資管理合伙企業(普通合伙)(18.01%);杭州中美華東制藥有限公司(16.17%);泰州洪泰健康投資管理中心(有限合伙)(8.44%);泰州信孚同心企業管理合伙企業(有限合伙)(7%) |
|---|
Market Sentiment
The IPO of 荃信生物－Ｂ (02509) saw strong demand, with 14,525 valid applications driving an oversubscription ratio of 163.15x. The overall hit rate of 29.17% indicates a moderately competitive allocation, though final pricing details were not available in the dataset. This level of enthusiasm aligns with a robust appetite for biotech listings, though it does not guarantee post-listing performance. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Tier Analysis
In tier distribution, the expected allocation for 甲尾 (200 lots applied) was only 0.05 lots, compared to 0.0902 lots for 乙头 (400 lots applied), resulting in a near-identical per-lot return despite the higher capital commitment at 乙头. This tiny allocation advantage for 甲尾, coupled with likely higher broker fees for B-tier applications, suggests an inefficient tier structure where small investors received marginally better value. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Demographics
The applicant base was heavily skewed toward mainland Chinese investors, who accounted for 84.6% of the 4,123 beneficial holders, compared to 15.3% from Hong Kong. Male participants slightly outnumbered females at 53.4% versus 46.6%, and the average age was 45.0 years, indicating a mature, cross-border investor profile with concentrated interest from mainland China. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
